Market capitalization | $41.59m |
Enterprise Value | $-104.98m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 1.33 |
EV/Sales (TTM) EV/Sales | -15.00 |
P/S ratio (TTM) P/S ratio | 5.94 |
P/B ratio (TTM) P/B ratio | 0.28 |
Revenue (TTM) Revenue | $7.00m |
EBIT (operating result TTM) EBIT | $-99.54m |
As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.
6 Analysts have issued a Kezar Life Sciences Inc forecast:
6 Analysts have issued a Kezar Life Sciences Inc forecast:
Dec '23 |
+/-
%
|
||
Revenue | 7 7 |
-
|
|
Gross Profit | 5.93 5.93 |
681%
681%
|
|
EBITDA | -104 -104 |
48%
48%
|
EBIT (Operating Income) EBIT | -105 -105 |
48%
48%
|
Net Profit | -102 -102 |
49%
49%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Kezar Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco, California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.
Head office | United States |
CEO | Christopher Kirk |
Employees | 58 |
Founded | 2015 |
Website | www.kezarlifesciences.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.